TY - JOUR
T1 - Critical role of interleukin (IL)-17 in inflammatory and immune disorders
T2 - An updated review of the evidence focusing in controversies
AU - Ruiz de Morales, José María G.
AU - Puig, Lluís
AU - Daudén, Esteban
AU - Cañete, Juan D.
AU - Pablos, José Luis
AU - Martín, Antonio Olveira
AU - Juanatey, Carlos González
AU - Adán, Alfredo
AU - Montalbán, Xavier
AU - Borruel, Natalia
AU - Ortí, Guillermo
AU - Holgado-Martín, Esther
AU - García-Vidal, Carolina
AU - Vizcaya-Morales, Cynthia
AU - Martín-Vázquez, Víctor
AU - González-Gay, Miguel Ángel
N1 - Publisher Copyright:
© 2019 The Authors
PY - 2020/1
Y1 - 2020/1
N2 - Interleukin 17 (IL-17) is a proinflammatory cytokine that has been the focus of intensive research because of its crucial role in the pathogenesis of different diseases across many medical specialties. In this context, the present review in which a panel of 13 experts in immunology, dermatology, rheumatology, neurology, hematology, infectious diseases, hepatology, cardiology, ophthalmology and oncology have been involved, puts in common the mechanisms through which IL-17 is considered a molecular target for the development of novel biological therapies in these different fields. A comprehensive review of the literature and analysis of the most outstanding evidence have provided the basis for discussing the most relevant data related to IL-17A blocking agents for the treatment of different disorders, such as psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, cardiovascular disorders, non alcoholic fatty liver disease, multiple sclerosis, inflammatory bowel disease, uveitis, hematological and solid cancer. Current controversies are presented giving an opening line for future research.
AB - Interleukin 17 (IL-17) is a proinflammatory cytokine that has been the focus of intensive research because of its crucial role in the pathogenesis of different diseases across many medical specialties. In this context, the present review in which a panel of 13 experts in immunology, dermatology, rheumatology, neurology, hematology, infectious diseases, hepatology, cardiology, ophthalmology and oncology have been involved, puts in common the mechanisms through which IL-17 is considered a molecular target for the development of novel biological therapies in these different fields. A comprehensive review of the literature and analysis of the most outstanding evidence have provided the basis for discussing the most relevant data related to IL-17A blocking agents for the treatment of different disorders, such as psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, cardiovascular disorders, non alcoholic fatty liver disease, multiple sclerosis, inflammatory bowel disease, uveitis, hematological and solid cancer. Current controversies are presented giving an opening line for future research.
KW - Biological drugs
KW - Citoquine
KW - IL17A
KW - Immunology
KW - Inflammation
KW - Psoriasis
UR - http://www.scopus.com/inward/record.url?scp=85076161228&partnerID=8YFLogxK
U2 - 10.1016/j.autrev.2019.102429
DO - 10.1016/j.autrev.2019.102429
M3 - Review article
C2 - 31734402
AN - SCOPUS:85076161228
SN - 1568-9972
VL - 19
JO - Autoimmunity Reviews
JF - Autoimmunity Reviews
IS - 1
M1 - 102429
ER -
